Advertisement

Topics

Servier and Transgene Have Become Partners to Apply Viral Vectorization Technology to the Engineering of Allogenic CAR-T

01:30 EDT 29 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Regulatory News: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170628006571/en/ Servier and Transgene (Paris:TNG), a biotechnology company that designs and...

Other Sources for this Article

Servier
Karine Bousseau
Servier External Communications
+33 1 5572 4021
+33 6 4992 1605
media@servier.com
or
Transgene
Lucie Larguier
Corporate Communication & Investor Relations Director
+33 (0)3 88 27 91 04
investorrelations@transgene.fr
or
Media Relations:
IMAGE 7
Claire Doligez/Laurence Heilbronn
+33 (0)1 53 70 74 48
cdoligez@image7.fr

NEXT ARTICLE

More From BioPortfolio on "Servier and Transgene Have Become Partners to Apply Viral Vectorization Technology to the Engineering of Allogenic CAR-T"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...